## Supplementary Information

## Mitochondria-Targeted Nanospheres with Deep Tumor Penetration

## for Photo/Starvation Therapy

Yong Wang,<sup>‡, a</sup> Bo Wang,<sup>‡, a</sup> Liang Zhang,<sup>‡, b</sup> Ju Huang,<sup>b</sup> Pan Li,<sup>b</sup> Yahui

Zhao,<sup>c</sup> Chen Zhou,<sup>a</sup> Mei Liu,<sup>c</sup> Weiwei Li,<sup>c</sup> Jie He<sup>\*d</sup>

<sup>a</sup>Department of Ultrasound, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

<sup>b</sup>Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.

<sup>c</sup>State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

<sup>d</sup>Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.



**Fig. S1** Digital photographs of PLGA-GOx and IR780@PLGA-GOx dispersed in PBS at concentrations of 10 mg/mL.



Fig. S2 Stability analysis of IR780@PLGA-GOx nanoparticles in PBS (a) and in serum (b).



**Fig. S3** Relative absorbance intensity of IR780 in UV-vis spectrum at the wavelength of 783 nm.



**Fig. S4** Infrared thermograms of IR780@PLGA-GOx suspensions irradiated with an 808 nm laser at different power intensities (0.75, 1.0, 1.25 and 1.5 W/cm<sup>2</sup>) and for various durations.



**Fig. S5** Infrared thermograms of IR780@PLGA-GOx suspensions at different concentrations (0, 1.25, 2.5, 3.75 and 5 mg/mL) irradiated with an 808 nm laser for various durations.



**Fig. S6** *In vitro* ROS generation of IR780@PLGA-GOx as assisted by irradiation with an 808 nm laser (1.5 W/cm<sup>2</sup>) for increasing durations. The concentration of IR780@PLGA-GOx was (a) 1 mg/mL (PLGA equivalence), (b) 2 mg/mL (PLGA equivalence), (c) 3 mg/mL (PLGA equivalence), or (d) 4 mg/mL (PLGA equivalence).



**Fig. S7** In vitro ROS generation of different concentrations of IR780@PLGA-GOx as assisted by irradiation with an 808 nm laser (1.5 W/cm<sup>2</sup>). The irradiation time was (a)

15 s, (b) 30 s, (c) 60 s, or (d) 90 s.



**Fig. S8** (a) Lineweaver–Burk plot of PLGA-GOx; (b) Michaelis–Menten kinetics of PLGA-GOx; (c) Lineweaver–Burk plot of GOx; (d) Michaelis–Menten kinetics of GOx.

- Contraction of the second se		
	<u> </u>	
		2 mm

Fig. S9 Tomographic scanning of tumor tissue in 25  $\mu$ m intervals after intravenous injection of IR780@PLGA-GOx.

G			Ś	$\langle 0 \rangle$
Q	0	)		9
	(J)		Q	0
O				
			(P)	
		and the second s		2 <u>mm</u>

Fig. S10 Tomographic scanning of tumor tissue with 25  $\mu m$  intervals after intravenous injection of PLGA-GOx.



**Fig. S11** PA intensity of IR780@PLGA-GOx excitation at wavelengths from 680 to 970 nm.



Fig. S12 Body weights of the mice in each group during the treatment period (n = 5).

![](_page_8_Figure_0.jpeg)

**Fig. S13** H&E staining of major organs, including the heart, liver, spleen, lungs and kidneys, of 4T1 tumor-bearing mice post treatment (scale bar: 100 µm).